WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

WilmerHale Represents Karyopharm in Agreement with Biogen to Acquire KPT-350

Firm News

On January 25, Karyopharm Therapeutics Inc. (NASDAQ:KPTI) announced its entry into an agreement for Biogen to acquire Karyopharm's investigational oral SINE compound KPT-350 and other assets for the treatment of certain neurological and neurodegenerative conditions. KPT-350 is a novel therapeutic candidate that works by inhibiting XPO1, resulting in reductions in inflammation and neurotoxicity, as well as increasing neuroprotective responses.

The WilmerHale team representing Karyopharm in this deal included Steve Singer and Andrew Bonnes.

The full press release can be found at www.karyopharm.com.  

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.